Indication
Congenital Bleeding Disorder
7 clinical trials
8 products
Product
Eptacog alfaClinical trial
A Long-Term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors. A Retrospective Follow-up Assessment to F7HAEM/USA/3/USA and F7HAEM/USA/4/USAStatus: Completed, Estimated PCD: 2011-08-01
Clinical trial
Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia BStatus: Completed, Estimated PCD: 2023-11-17
Product
Nonacog Beta PegolClinical trial
An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)Status: Completed, Estimated PCD: 2022-10-27
Product
Nonacog beta pegolProduct
Turoctocog Alfa PegolClinical trial
An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia AStatus: Completed, Estimated PCD: 2023-06-07
Product
N9-GPProduct
ALPROLIX®Clinical trial
A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia BStatus: Completed, Estimated PCD: 2017-12-08
Product
Turoctocog alfa pegolClinical trial
Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia AStatus: Completed, Estimated PCD: 2020-12-03
Product
Recombinant factor XIIIClinical trial
A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in JapanStatus: , Estimated PCD: 2024-09-30